Ironwood Pharma (NASDAQ:IRWD) reported Q1 EPS of $0.21, $0.04 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $98 million versus the consensus estimate of $93.97 million.
GUIDANCE:
Ironwood Pharma sees FY2022 revenue of $420-430 million, versus the consensus of $430 million.